Cited 19 times in
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승업 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이현웅 | - |
dc.date.accessioned | 2020-12-11T07:51:06Z | - |
dc.date.available | 2020-12-11T07:51:06Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0017-5749 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180685 | - |
dc.description.abstract | Objective: Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs: This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results: During follow-up (median=26.9 months, IQR=12.2-49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion: The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | British Medical Assn. | - |
dc.relation.isPartOf | GUT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Minseok Albert Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Dong Hyun Sinn | - |
dc.contributor.googleauthor | Jeong Won Jang | - |
dc.contributor.googleauthor | Young-Suk Lim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Jae-Jun Shim | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Yang Hyun Baek | - |
dc.contributor.googleauthor | Sang Gyune Kim | - |
dc.contributor.googleauthor | Young Seok Kim | - |
dc.contributor.googleauthor | Ji Hoon Kim | - |
dc.contributor.googleauthor | Won Hyeok Choe | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | Jung Hyun Kwon | - |
dc.contributor.googleauthor | Sung Won Lee | - |
dc.contributor.googleauthor | Jae Young Jang | - |
dc.contributor.googleauthor | Hwi Young Kim | - |
dc.contributor.googleauthor | Yewan Park | - |
dc.contributor.googleauthor | Gi-Ae Kim | - |
dc.contributor.googleauthor | Hyun Yang | - |
dc.contributor.googleauthor | Han Ah Lee | - |
dc.contributor.googleauthor | Myeongseok Koh | - |
dc.contributor.googleauthor | Young-Sun Lee | - |
dc.contributor.googleauthor | Minkoo Kim | - |
dc.contributor.googleauthor | Young Chang | - |
dc.contributor.googleauthor | Yoon Jun Kim | - |
dc.contributor.googleauthor | Jung-Hwan Yoon | - |
dc.contributor.googleauthor | Fabien Zoulim | - |
dc.contributor.googleauthor | Jeong-Hoon Lee | - |
dc.identifier.doi | 10.1136/gutjnl-2019-320015 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03292 | - |
dc.relation.journalcode | J00953 | - |
dc.identifier.eissn | 1468-3288 | - |
dc.identifier.pmid | 32209606 | - |
dc.identifier.url | https://gut.bmj.com/content/69/12/2214.long | - |
dc.subject.keyword | HBV DNA redetection | - |
dc.subject.keyword | HBsAg | - |
dc.subject.keyword | antivirals | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.citation.volume | 69 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2214 | - |
dc.citation.endPage | 2222 | - |
dc.identifier.bibliographicCitation | GUT, Vol.69(12) : 2214-2222, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.